Twinbeech Capital LP bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,001 shares of the company's stock, valued at approximately $367,000.
Several other institutional investors and hedge funds also recently made changes to their positions in GH. KBC Group NV raised its stake in Guardant Health by 63.6% during the 4th quarter. KBC Group NV now owns 5,658 shares of the company's stock worth $173,000 after buying an additional 2,200 shares during the period. R Squared Ltd purchased a new stake in shares of Guardant Health in the fourth quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Guardant Health by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,198 shares of the company's stock worth $800,000 after purchasing an additional 2,537 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares during the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of Guardant Health in the fourth quarter worth approximately $377,000. Institutional investors own 92.60% of the company's stock.
Insider Buying and Selling
In related news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 107,132 shares of company stock worth $5,248,393. Corporate insiders own 6.10% of the company's stock.
Guardant Health Price Performance
Shares of Guardant Health stock traded down $0.69 during trading hours on Wednesday, reaching $38.48. The company had a trading volume of 397,515 shares, compared to its average volume of 2,137,011. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92. The business has a fifty day simple moving average of $43.11 and a 200 day simple moving average of $40.30. The firm has a market cap of $4.77 billion, a PE ratio of -10.81 and a beta of 1.49.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same period last year, the company earned ($0.46) earnings per share. The business's revenue for the quarter was up 20.8% on a year-over-year basis. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.
Analysts Set New Price Targets
Several brokerages have recently commented on GH. Stephens reissued an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Morgan Stanley increased their price target on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Canaccord Genuity Group increased their price target on Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Finally, Guggenheim reaffirmed a "buy" rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Twenty-one research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $52.32.
Check Out Our Latest Analysis on GH
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Articles
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
